Schellenberger and colleagues engineer masked, conditionally active T-cell engagers targeting tumor antigens and CD3 and show potent, protease-dependent antitumor activity in mouse models, as well as safety in non-human primates.
- Fiore Cattaruzza
- Ayesha Nazeer
- Volker Schellenberger
